Cardiff Oncology, Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-01-02

Reporting Person: Kelemen Vicki (Exec. VP and COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-02	Common Stock	M	70	—	Acquired	5124	Direct
2021-01-02	Common Stock	F	31	—	Disposed	5093	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-02	Restricted Stock Units	$	M	70	Disposed		Common Stock (70.0)	Direct

Footnotes

F1: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 3 filed with the Securities and Exchange Commission on June 22, 2020.

F2: The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 31 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021.

F3: Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock.

F4: On January 4, 2017, the reporting person was granted 278 restricted stock units, 70 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4.